Humacyte (HUMA) Change in Accured Expenses (2020 - 2026)

Humacyte (HUMA) has reported Change in Accured Expenses for 7 consecutive years, with -$2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 3.66% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$1.6 million (down 178.25% YoY), while the FY2025 annual figure was -$1.7 million, down 176.36% from the prior year.
• Change in Accured Expenses retreated to -$2.2 million in Q1 2026 per HUMA's latest filing, from -$263000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.3 million in Q3 2023 and bottomed at -$2.3 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $19941.2 across 5 years, with a median of -$136000.0 in 2025.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 318.72% — and 2024, when it soared 1585.04%.
• Humacyte's Change in Accured Expenses stood at -$1.4 million in 2022, then jumped by 70.18% to -$410000.0 in 2023, then surged by 162.93% to $258000.0 in 2024, then tumbled by 201.94% to -$263000.0 in 2025, then slumped by 730.42% to -$2.2 million in 2026.
• Business Quant data shows HUMA's Change in Accured Expenses at -$2.2 million in Q1 2026, -$263000.0 in Q4 2025, and $957000.0 in Q3 2025.